Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$13.70 USD
+0.08 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $13.69 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CATX 13.70 +0.08(0.59%)
Will CATX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CATX
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Other News for CATX
Perspective Therapeutics initiated with bullish view at BofA, here's why
3 Outperforming Stocks Surpassing Even Nvidia This Year
BofA starts Perspective at buy, cites use of radioactive Lead-212
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
Buy Rating Maintained for Perspective Therapeutics Amidst Positive Long-Term Growth Prospects and Upcoming Clinical Catalysts